List view / Grid view

Dr Raminderpal Singh (Hitchhikers AI and 20/15 Visioneers)

 

article

The evolution of AI in drug discovery: learning from history’s mistakes (Part 1)

AI is transforming drug discovery, but its adoption mirrors past…

14 March 2025 | By ,

AI is transforming drug discovery, but its adoption mirrors past technological shifts in the industry. In this first part of a two-part series, we reveal Sujeegar Jeevanandam’s observations of the parallels between AI and the electronic lab notebook revolution, highlighting key challenges, lessons learned, and what the future holds for…

article

Large language models: now more affordable and reliable than ever

In this article, Dr Raminderpal Singh explores the transformative impact…

24 February 2025 | By

In this article, Dr Raminderpal Singh explores the transformative impact of the Deepseek R1 open-source large language model on drug discovery.  Its potential offers exciting opportunities for both scientists and software developers, marking a significant advancement for the life sciences community.

article

An industry leader’s perspective on the complexity of scientific data

In this article, Dr Raminderpal Singh speaks to Janette Thomas…

24 October 2024 | By

In this article, Dr Raminderpal Singh speaks to Janette Thomas of Five Alarm Bio for a biotech CEO’s perspective on the complexity of data faced by both large and small biotechs. Janette is on a mission to develop drugs targeting the chronic diseases associated with ageing. She shares her insights…

article

Bridging science and technology: a biotech CEO’s perspective

In this article, Dr Raminderpal Singh speaks to Neil Wilkie…

14 October 2024 | By

In this article, Dr Raminderpal Singh speaks to Neil Wilkie of Mironid Ltd. for a biotech CEO’s perspective on the transformative potential of AI, and the importance of bridging communication gaps between scientific and technical teams to drive innovation and efficiency in the pharmaceutical industry.

article

Part three: pragmatic guidelines to getting the best out of LLMs

There have been a slew of announcements over the past…

24 July 2024 | By

There have been a slew of announcements over the past few months from AI-led biotechs around the potential of Large Language Models (LLM) in early drug discovery. In the third of a three-part series, Dr Raminderpal Singh presents some pragmatic guidelines for scientists in accessing and obtaining value from LLMs.

article

Part two: how ChatGPT enriched animal study results

Recently there has been a flurry of announcements from AI-led…

15 July 2024 | By

Recently there has been a flurry of announcements from AI-led biotechs around the potential of Large Language Models (LLM) in early drug discovery. In the second of a three-part series, Dr Raminderpal Singh presents an example of usage of ChatGPT, which demonstrates how accessible LLMs have become for lab scientists.

article

Part one: what can scientists do with LLMs today?

Recently there have been a flurry of announcements from AI-led…

24 June 2024 | By

Recently there have been a flurry of announcements from AI-led biotechs around the potential of Large Language Models (LLM) in early drug discovery. In the first of a three-part series, Dr Raminderpal Singh explores what LLMs are, how early stage biotechs can take advantage of them, and what challenges they…

article

Kickstarting the use of AI for biotechs: part three

Traditional wet lab scientists working on target discovery, drug identification…

20 June 2024 | By

Traditional wet lab scientists working on target discovery, drug identification and drug optimisation have an opportunity to catch up with their AI-enabled peers – but why should they, and how? In this article – the third of a three-part series – Dr Raminderpal Singh touches on the decisions that need…

article

Kickstarting the use of AI for biotechs: part two

Traditional wet lab scientists working on target discovery, drug identification…

24 May 2024 | By

Traditional wet lab scientists working on target discovery, drug identification and drug optimisation have an opportunity to catch up with their AI-enabled peers – but why should they, and how? In this article – the second of a three-part series – Dr Raminderpal Singh touches on methods that are being…

article

Kickstarting the use of AI for biotechs: part one

Traditional wet lab scientists working on target discovery, drug identification…

15 May 2024 | By

Traditional wet lab scientists working on target discovery, drug identification and drug optimisation have an opportunity to catch-up with their AI-enabled peers – but why should they, and how? In this article – the first of a three-part series – Dr Raminderpal Singh seeks to demystify the topic by outlining…